Kynam Capital Management’s Caribou Biosciences CRBU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.18M Hold
2,503,302
– – 0.18% 31
2026
Q2
$4.41M Hold
2,503,302
– – 0.24% 28
2026
Q1
$4.76M Hold
2,503,302
– – 0.29% 35
2025
Q4
$3.98M Sell
2,503,302
-564,472
-18% -$1.18M 0.25% 32
2025
Q3
$7.15M Hold
3,067,774
– – 0.53% 29
2025
Q2
$3.87M Sell
3,067,774
-201,373
-6% -$198K 0.42% 24
2025
Q1
$2.99M Buy
3,269,147
+863,000
+36% +$1.12M 0.25% 29
2024
Q4
$3.83M Buy
2,406,147
+50,000
+2% +$101K 0.23% 28
2024
Q3
$4.62M Buy
2,356,147
+709,445
+43% +$1.45M 0.35% 23
2024
Q2
$2.7M Buy
1,646,702
+578,175
+54% +$1.85M 0.21% 25
2024
Q1
$5.49M Hold
1,068,527
– – 0.57% 21
2023
Q4
$6.12M Hold
1,068,527
– – 0.68% 22
2023
Q3
$5.11M Buy
+1,068,527
New +$6.63M 0.84% 21

Other funds holding CRBU

Kynam Capital Management's CRBU Position: Q3 2026 in Review

Kynam Capital Management held its Caribou Biosciences (CRBU) position steady in Q3 2026 at 2,503,302 shares worth $3.18M. The position accounts for 0.18% of the portfolio, ranked #31.

Kynam Capital Management first reported a position in CRBU in Q3 2023 and has held it in 13 quarters since. The position peaked at $7.15M in Q3 2025. 144 funds tracked by Wall St. Rank hold CRBU as of Q3 2026.

  • Kynam Capital Management held 2,503,302 shares of Caribou Biosciences worth $3.18M as of Q3 2026.
  • Kynam Capital Management left its Caribou Biosciences share count unchanged in Q3 2026.
  • Caribou Biosciences made up 0.18% of Kynam Capital Management's portfolio in Q3 2026, its #31 holding.
  • Kynam Capital Management first reported a position in Caribou Biosciences in Q3 2023 and has held it in 13 quarters since.
  • Kynam Capital Management's Caribou Biosciences position peaked at $7.15M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2026.

Based on Kynam Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.